Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stem cell therapy shows promise for rescuing deteriorating vision

29.03.2007
For the millions of Americans whose vision is slowly ebbing due to degenerative diseases of the eye, the lowly neural progenitor cell may be riding to the rescue.

In a study in rats, neural progenitor cells derived from human fetal stem cells have been shown to protect the vision of animals with degenerative eye disease similar to the kinds of diseases that afflict humans. The new study appears today (March 28) in the journal Public Library of Science (PLoS) One.

The lead author of the study, University of Wisconsin-Madison researcher David Gamm, says the cells - formative brain cells that arise in early development - show "some of the best rescue, functionally and anatomically" of any such work to date. In animals whose vision would typically be lost to degenerative retinal disease, the cells were shown to protect vision and the cells in the eye that underpin sight.

The new findings are important because they suggest there may be novel ways to preserve vision in the context of degenerative diseases for which there are now no effective treatments. Macular degeneration, an age-related affliction that gradually destroys central vision, is a scourge of old age, robbing people of the ability to read, recognize faces and live independently.

The finding that the brain cells protected the cells in the eye was a surprise, according to Raymond D. Lund, an author of the new study and an eye disease expert at the University of Utah and the Oregon Health and Sciences University. The neural progenitor cells, which arise from stem cells and further differentiate into different types of cells found in the central nervous system, were being tested for their ability to deliver another agent, a growth factor that has been shown to be effective in treating some types of degenerative disease.

What was surprising, say Gamm and Lund, was that the cells alone demonstrated a remarkable ability to rescue vision.

"On their own, they were able to support retinal cells and keep them alive," says Lund, who has conducted pioneering studies of cell therapy for eye disease. "We didn't expect that at all. We've used a number of different cell types from different sources and these have given us the best results we've ever got."

How the cells act to preserve the deteriorating eye cells remains unknown, says Gamm. Like all cells, neural progenitor cells do many things and secrete many different types of chemicals that may influence the cells around them.

"The idea was to test the cells as a continuous delivery system" to shuttle an agent known as glial cell line-derived neurotrophic factor or GDNF, Lund explains. "It's not a sensible thing to inject the eyes many times over years. The idea was to use the cells as a continuous delivery system, but we found they work quite well on their own."

Lund has experimented with other cell types as therapies for preserving vision. The neural progenitor cells, a cell model developed by Wisconsin stem cell researcher Clive Svendsen, have been used experimentally to deliver the same growth factor in models of Parkinson's disease and Lou Gehrig's disease. Svendsen is also an author of the new PloS One report.

"It seems that the cells in and of themselves are quite neuroprotective," says Gamm. "They don't become retinal cells. They maintain their own identity, but they migrate within the outer and inner retina" where they seem to confer some protection to the light-sensing cells that typically die in the course of degenerative eye disease.

For researchers, the work is intriguing because the progenitor cells come from the brain itself, and not from the part of the nervous system devoted to vision.

"This cell type isn't derived from the retina. It is derived from the brain," says Gamm. "But we're not asking it to become a retina. They survive in the environment of the eye and don't disrupt the local architecture. They seem to live in a symbiotic relation ship" with retinal cells.

Gamm and Lund emphasize that the new work is preliminary, and that much remains to be done before the cells can be tested in humans: "The first thing is to show that something works, which we have done," says Lund. "Now we need to find out why, but this is a good jumping off point. "

David Gamm | EurekAlert!
Further information:
http://www.wisc.edu

More articles from Health and Medicine:

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

nachricht Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection

13.11.2018 | Life Sciences

Fish recognize their prey by electric colors

13.11.2018 | Life Sciences

Ultrasound Connects

13.11.2018 | Awards Funding

VideoLinks
Science & Research
Overview of more VideoLinks >>>